Jenscare Scientific's (HKG:9877) attributable loss narrowed 52% to 177.5 million yuan in 2024 from 371.7 million yuan in 2023, according to a Friday filing with the Hong Kong bourse.
Loss per share at the pharmaceutical company narrowed 52% to 0.43 yuan from 0.89 yuan in the previous year.
Jenscare did not disclose revenue for both 2024 and 2023.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。